Jakavi Ruxolitinib 20mg Tablet

About Jakavi Ruxolitinib 20mg Tablet

Jakavi 20mg Tablet contains Ruxolitinib, a targeted kinase inhibitor used to treat certain blood and bone marrow disorders, including myelofibrosis, a rare cancer that disrupts normal blood cell production, and polycythemia vera, a blood cancer characterized by excessive red blood cell production in patients who are resistant to or unable to tolerate hydroxyurea. It is also approved for the treatment of acute and chronic graft-versus-host disease (GVHD) in adults and children aged 12 years and older who have not responded adequately to corticosteroids or other systemic therapies. Ruxolitinib works by blocking specific signaling pathways that contribute to abnormal cell growth and inflammation, helping to control disease symptoms, reduce spleen enlargement, and improve overall quality of life. Patients should not take Jakavi 20mg Tablet if they are allergic to Ruxolitinib or any of its ingredients. Before starting treatment, it is important to inform your healthcare provider about any history of tuberculosis, hepatitis B or C infection, liver disease, kidney disorders, or dialysis treatment, as these conditions may require closer monitoring. Common side effects may include dizziness, headache, bruising, bleeding, swelling of the face or body, and reduced blood cell counts, which can increase the risk of infections, anemia, or bleeding complications. Regular blood tests and medical follow-up are essential during treatment to monitor response and manage potential side effects. Jakavi 20mg Tablet is widely used in modern hematology to provide effective long-term management of complex blood cancers and transplant-related immune complications.